SLDB
Live chart
What they do
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial.
For information only · Important disclosures
Grades vs sector
No sector grades for SLDB yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.47 | -0.38 | +18.9% |
| 2026-03-19 | -0.52 | -0.53 | -1.9% |
| 2025-11-03 | -0.44 | -0.48 | -8.9% |
| 2025-08-12 | -0.49 | -0.42 | +14.6% |
| 2025-05-15 | -0.54 | -0.59 | -9.1% |
| 2025-03-06 | -0.78 | -1.00 | -27.8% |
| 2024-11-06 | -0.66 | -0.79 | -20.3% |
| 2024-08-13 | -0.66 | -0.61 | +7.8% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$24.6K
–
Stats refreshed 2026-10-21 12:15:10 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026